(A) Overall clearances and (B) reduction ratios of medium-sized and small molecules in treatments in study 2
| Cases . | MCO AA HD . | MCO BB HD . | High-flux HD . | HDF . |
|---|---|---|---|---|
| (A) Overall clearance (mL/min) | ||||
| α1-microglobulin | 3.3 (0.20)* | 4.6 (0.20)* | 0.4 (0.20) | 1.3 (0.20) |
| Complement factor D | 26.3 (1.13)* | 32.8 (1.10)* | 8.2 (1.10) | 12.4 (1.10) |
| Myoglobin | 58.7 (2.46)* | 62.7 (2.39)* | 19.9 (2.39) | 35.6 (2.46) |
| β2-microglobulin | 84.7 (3.18)**,*** | 84.3 (3.10)**,*** | 55.1 (3.10) | 73.1 (3.18) |
| Creatinine | 210.4 (8.73) | 203.7 (8.31) | 208.9 (8.31) | 210.0 (8.31) |
| Phosphate | 209.8 (11.29) | 218.0 (10.71) | 193.2 (10.71) | 194.5 (10.71) |
| Urea | 281.9 (11.97) | 268.1 (11.32) | 277.0 (11.32) | 263.4 (11.32) |
| (B) Reduction ratio (%) | ||||
| YKL-40 | 63.6 (2.21)* | 68.8 (2.21)* | 29.8 (2.21) | 44.8 (2.21) |
| α1-microglobulin | 24.8 (8.97)*** | 30.1 (8.97)*** | 10.0 (8.97) | −8.9 (8.97) |
| Complement factor D | 63.0 (1.73)* | 66.7 (1.73)* | 32.9 (1.73) | 46.3 (1.73) |
| Myoglobin | 67.9 (2.34)* | 71.6 (2.34)* | 37.2 (2.34) | 59.3 (2.37) |
| β2-microglobulin | 78.5 (1.32)**,**** | 78.9 (1.32)** | 73.5 (1.32) | 80.6 (1.33) |
| Creatinine | 73.5 (1.45) | 73.2 (1.45) | 71.7 (1.45) | 73.7 (1.45) |
| Phosphate | 52.8 (2.13) | 48.8 (2.13) | 48.4 (2.13) | 51.0 (2.13) |
| Urea | 80.7 (1.33)***** | 80.3 (1.33)**** | 79.4 (1.33) | 81.6 (1.33) |
| Cases . | MCO AA HD . | MCO BB HD . | High-flux HD . | HDF . |
|---|---|---|---|---|
| (A) Overall clearance (mL/min) | ||||
| α1-microglobulin | 3.3 (0.20)* | 4.6 (0.20)* | 0.4 (0.20) | 1.3 (0.20) |
| Complement factor D | 26.3 (1.13)* | 32.8 (1.10)* | 8.2 (1.10) | 12.4 (1.10) |
| Myoglobin | 58.7 (2.46)* | 62.7 (2.39)* | 19.9 (2.39) | 35.6 (2.46) |
| β2-microglobulin | 84.7 (3.18)**,*** | 84.3 (3.10)**,*** | 55.1 (3.10) | 73.1 (3.18) |
| Creatinine | 210.4 (8.73) | 203.7 (8.31) | 208.9 (8.31) | 210.0 (8.31) |
| Phosphate | 209.8 (11.29) | 218.0 (10.71) | 193.2 (10.71) | 194.5 (10.71) |
| Urea | 281.9 (11.97) | 268.1 (11.32) | 277.0 (11.32) | 263.4 (11.32) |
| (B) Reduction ratio (%) | ||||
| YKL-40 | 63.6 (2.21)* | 68.8 (2.21)* | 29.8 (2.21) | 44.8 (2.21) |
| α1-microglobulin | 24.8 (8.97)*** | 30.1 (8.97)*** | 10.0 (8.97) | −8.9 (8.97) |
| Complement factor D | 63.0 (1.73)* | 66.7 (1.73)* | 32.9 (1.73) | 46.3 (1.73) |
| Myoglobin | 67.9 (2.34)* | 71.6 (2.34)* | 37.2 (2.34) | 59.3 (2.37) |
| β2-microglobulin | 78.5 (1.32)**,**** | 78.9 (1.32)** | 73.5 (1.32) | 80.6 (1.33) |
| Creatinine | 73.5 (1.45) | 73.2 (1.45) | 71.7 (1.45) | 73.7 (1.45) |
| Phosphate | 52.8 (2.13) | 48.8 (2.13) | 48.4 (2.13) | 51.0 (2.13) |
| Urea | 80.7 (1.33)***** | 80.3 (1.33)**** | 79.4 (1.33) | 81.6 (1.33) |
LS mean +/- standard error
Comparisons are based on a mixed model with fixed effects of period and study dialyzer type, and the random effect of subject.
*P < 0.001 versus HD and HDF; **P < 0.001 versus HD; ***P < 0.01 versus HDF; ****P < 0.05 versus HDF; *****P < 0.05 versus HD.
(A) Overall clearances and (B) reduction ratios of medium-sized and small molecules in treatments in study 2
| Cases . | MCO AA HD . | MCO BB HD . | High-flux HD . | HDF . |
|---|---|---|---|---|
| (A) Overall clearance (mL/min) | ||||
| α1-microglobulin | 3.3 (0.20)* | 4.6 (0.20)* | 0.4 (0.20) | 1.3 (0.20) |
| Complement factor D | 26.3 (1.13)* | 32.8 (1.10)* | 8.2 (1.10) | 12.4 (1.10) |
| Myoglobin | 58.7 (2.46)* | 62.7 (2.39)* | 19.9 (2.39) | 35.6 (2.46) |
| β2-microglobulin | 84.7 (3.18)**,*** | 84.3 (3.10)**,*** | 55.1 (3.10) | 73.1 (3.18) |
| Creatinine | 210.4 (8.73) | 203.7 (8.31) | 208.9 (8.31) | 210.0 (8.31) |
| Phosphate | 209.8 (11.29) | 218.0 (10.71) | 193.2 (10.71) | 194.5 (10.71) |
| Urea | 281.9 (11.97) | 268.1 (11.32) | 277.0 (11.32) | 263.4 (11.32) |
| (B) Reduction ratio (%) | ||||
| YKL-40 | 63.6 (2.21)* | 68.8 (2.21)* | 29.8 (2.21) | 44.8 (2.21) |
| α1-microglobulin | 24.8 (8.97)*** | 30.1 (8.97)*** | 10.0 (8.97) | −8.9 (8.97) |
| Complement factor D | 63.0 (1.73)* | 66.7 (1.73)* | 32.9 (1.73) | 46.3 (1.73) |
| Myoglobin | 67.9 (2.34)* | 71.6 (2.34)* | 37.2 (2.34) | 59.3 (2.37) |
| β2-microglobulin | 78.5 (1.32)**,**** | 78.9 (1.32)** | 73.5 (1.32) | 80.6 (1.33) |
| Creatinine | 73.5 (1.45) | 73.2 (1.45) | 71.7 (1.45) | 73.7 (1.45) |
| Phosphate | 52.8 (2.13) | 48.8 (2.13) | 48.4 (2.13) | 51.0 (2.13) |
| Urea | 80.7 (1.33)***** | 80.3 (1.33)**** | 79.4 (1.33) | 81.6 (1.33) |
| Cases . | MCO AA HD . | MCO BB HD . | High-flux HD . | HDF . |
|---|---|---|---|---|
| (A) Overall clearance (mL/min) | ||||
| α1-microglobulin | 3.3 (0.20)* | 4.6 (0.20)* | 0.4 (0.20) | 1.3 (0.20) |
| Complement factor D | 26.3 (1.13)* | 32.8 (1.10)* | 8.2 (1.10) | 12.4 (1.10) |
| Myoglobin | 58.7 (2.46)* | 62.7 (2.39)* | 19.9 (2.39) | 35.6 (2.46) |
| β2-microglobulin | 84.7 (3.18)**,*** | 84.3 (3.10)**,*** | 55.1 (3.10) | 73.1 (3.18) |
| Creatinine | 210.4 (8.73) | 203.7 (8.31) | 208.9 (8.31) | 210.0 (8.31) |
| Phosphate | 209.8 (11.29) | 218.0 (10.71) | 193.2 (10.71) | 194.5 (10.71) |
| Urea | 281.9 (11.97) | 268.1 (11.32) | 277.0 (11.32) | 263.4 (11.32) |
| (B) Reduction ratio (%) | ||||
| YKL-40 | 63.6 (2.21)* | 68.8 (2.21)* | 29.8 (2.21) | 44.8 (2.21) |
| α1-microglobulin | 24.8 (8.97)*** | 30.1 (8.97)*** | 10.0 (8.97) | −8.9 (8.97) |
| Complement factor D | 63.0 (1.73)* | 66.7 (1.73)* | 32.9 (1.73) | 46.3 (1.73) |
| Myoglobin | 67.9 (2.34)* | 71.6 (2.34)* | 37.2 (2.34) | 59.3 (2.37) |
| β2-microglobulin | 78.5 (1.32)**,**** | 78.9 (1.32)** | 73.5 (1.32) | 80.6 (1.33) |
| Creatinine | 73.5 (1.45) | 73.2 (1.45) | 71.7 (1.45) | 73.7 (1.45) |
| Phosphate | 52.8 (2.13) | 48.8 (2.13) | 48.4 (2.13) | 51.0 (2.13) |
| Urea | 80.7 (1.33)***** | 80.3 (1.33)**** | 79.4 (1.33) | 81.6 (1.33) |
LS mean +/- standard error
Comparisons are based on a mixed model with fixed effects of period and study dialyzer type, and the random effect of subject.
*P < 0.001 versus HD and HDF; **P < 0.001 versus HD; ***P < 0.01 versus HDF; ****P < 0.05 versus HDF; *****P < 0.05 versus HD.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
